Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs
SII.TO 5.37IPCO.TO -0.2DC.A.TO 0.28NESN-SIX 0MCK 27.62GOOG -1.47XLV 0.985TEVA 0.82
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

28.45
+0.48 (1.70%)
as of Aug 25, 2026, 5:51:24 pm Market Open.
582 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconAug 25, 2026, 12:00 am

This summary was created by AI, based on 24 opinions in the last 12 months.

Pfizer Inc. (PFE) is facing significant challenges as it navigates a patent cliff following the success of its COVID-19 vaccine. Many experts are concerned about its ability to generate new blockbuster drugs and the sustainability of its high dividend yields, which currently range from 6.4% to 7%. Several reviews emphasize that while the dividend is attractive, the company lacks earnings momentum and has uncertainty surrounding its drug pipeline. The stock trades at low earnings multiples, suggesting it may be undervalued, but experts warn that the lack of growth drivers could limit upside potential. Overall, patience may be required for investors looking for signs of recovery or growth in the company's future, especially as its recent acquisitions are yet to yield significant results.

consensus icon
Consensus
Neutral
valuation icon
Valuation
Undervalued
review icon
Similar
MRK
TOP PICK

Pfizer Inc(PFE)

Sep 03, 2004
Best U.S. drug company. They have new products that were just introduced. Own Lipridor, the largest drug.
Photo of Jackee PrattJackee Pratt
Owned
Unlock Rating
$32.55

Stock price when the opinion was issued

$28.35

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
Track your Stocks in your Watch List
TRADE

Pfizer Inc(PFE)

Aug 30, 2004
Long-term: it is a good investment.
Photo of John ZechnerJohn ZechnerUnlock Rating
$32.46

Stock price when the opinion was issued

$28.35

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Aug 25, 2004
A lot of the US drug stocks got ahead of themselves for the last couple of years. Actually looks pretty good now. At about 20X earnings now.
Photo of Bruce Campbell (1)Bruce Campbell (1)
No
Unlock Rating
$31.91

Stock price when the opinion was issued

$28.35

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Aug 24, 2004
This is one of those stocks which everyone loves. This means everyone owns it, which concludes no one will buy any more. It is in a negative trend.
Photo of Ron MeiselsRon Meisels
No
Unlock Rating
$31.53

Stock price when the opinion was issued

$28.35

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Aug 16, 2004
Has the highest yield and lowest PE that it has had for many many years. Good product pipeline. The stocks and biotechnology will do well in this decade. Hold for 1 to 2 years.
Photo of Rob CallanderRob Callander
Owned
Unlock Rating
$31.40

Stock price when the opinion was issued

$28.35

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Jul 28, 2004
It has not been a good month for pharmaceuticals. US election is causing some uncertainty which has put some pressure on the stock. A world-class company. Good revenue growth. Looking at about 13 X 2005 earnings.
Photo of John Sinkins, CFAJohn Sinkins, CFA
Owned
Unlock Rating
$31.62

Stock price when the opinion was issued

$28.35

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Jul 27, 2004
An excellent company, but there are other places they would rather invest in, such as Johnson and Johnson. Under attack by generic products.
Photo of Ian NakamotoIan Nakamoto
No
Unlock Rating
$32.10

Stock price when the opinion was issued

$28.35

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Jul 20, 2004
Sector analysis indicates more distribution than new accumulation so in general, pharmaceuticals are underperforming. They were treated as defensive holdings during the bear market. Since then, earnings haven't been strong enough to sustain valuation.
Photo of David BurrowsDavid Burrows
No
Unlock Rating
$32.33

Stock price when the opinion was issued

$28.35

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Jul 19, 2004
A great name for a long-term holding. A more conservative guidance brought the stock down. Drug stocks tend to do best when interest rates are rising.
Photo of Norman LevineNorman LevineUnlock Rating
$32.11

Stock price when the opinion was issued

$28.35

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
WEAK BUY

Pfizer Inc(PFE)

Jul 12, 2004
Like this sector. Good name. Growth potential is good.
Photo of Ray SteeleRay Steele
No
Unlock Rating
$33.63

Stock price when the opinion was issued

$28.35

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Jul 09, 2004
Likes the quality stocks, especially the health related ones.
Photo of Lou HollandLou Holland
Owned
Unlock Rating
$34.00

Stock price when the opinion was issued

$28.35

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Jun 04, 2004
One of the world's best drug companies and as cheap as it's been in the long, long time.
Photo of Lou HollandLou Holland
Owned
Unlock Rating
$35.62

Stock price when the opinion was issued

$28.35

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
TRADE

Pfizer Inc(PFE)

May 25, 2004
Large, US pharmaceutical stocks typically do well in a rising interest rate environment.
Photo of Neil WickhamNeil WickhamUnlock Rating
$34.74

Stock price when the opinion was issued

$28.35

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

May 14, 2004
Photo of Gene HensslerGene Henssler
Owned
Unlock Rating
$35.53

Stock price when the opinion was issued

$28.35

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

May 13, 2004
A lot of international sales. Have one of the strongest pipelines. A great core holding.
Photo of Bob StodgellBob Stodgell
Owned
Unlock Rating
$35.40

Stock price when the opinion was issued

$28.35

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
Showing 721 to 735 of 887 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

NTR.TO -1.69$101.18
TFPM 0$
OGC.TO 0.03$43.25
SLB -0.545$53.455
ARG.TO 0.53$8.75

Today's Top Picks

SII.TO 5.37$192.56
IPCO.TO -0.2$35.02
DC.A.TO 0.28$5.43
NESN-SIX 0$
MCK 27.62$901.41

Popular Articles

Latest Sell Signals

RKLB -1.16$67.12
INTC 0.36$87.62
MSFT 3.13$490.44
WSP.TO -3.61$188.67
CLS.TO 12.54$419.9

Most Recent Experts

Rick Rule

Rick Rule

Rule Investment Media

Jim Cramer - Mad Money

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Rob Sechan, Managing Partner, New Edge Capital

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Jenny Harrington, CEO, Gilman Hill Asset Management

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica

You may also like